Clinical Trials Directory

Are you interested in taking part in a clinical trial? Our Clinical Trials Directory includes all active clinical trials at The University of Tennessee Medical Center.

Moving Medical Knowledge Forward, Every Day

Doctors and researchers at The University of Tennessee Medical Center work together diligently. Our goal is to discover new and better ways to find and treat disease. We do this through various research projects and clinical trials.

Research projects at the medical center help move forward medical knowledge. The National Institutes of Health and related agencies fund researchers on our campus to bring the best of medical care to East Tennessee. Plus, our physicians provide clinical trial opportunities for our patients. We make them readily available to those who seek new medications and treatment.

Our research teams work closely with researchers throughout the University of Tennessee system as well as others throughout the nation.

The University of Tennessee Medical Center brings together outstanding patient care, challenging clinical training and stimulating research – all on one campus.

Find a Clinical Trial

B-Cell Lymphoma 

Cellectar Biosciences- Cellectar Biosciences open label, multicenter, Phase II study of CLR 131 in patients with relapsed or refractory select B-cell malignancies and expansion cohort in patients with Waldenstrom Macroglobulinemia clinical trial.

Genmab- A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Bladder Cancer

EGOG-EA8185- Phase II Study of Bladder-Sparing Chemoradiation with Durvalumab in Clinical Stage III

Breast Cancer

Alliance A011801- The compassher2 trials (comprehensive use of pathologic response assessment to optimize therapy in her2-positive breast cancer): A double-blinded, phase III randomized trial of t-dm1 and placebo compared with t-dm1 and tucatinib.

Merck MK3475-B49– a randomized, double-blind, placebo-controlled, Phase III study of Pembrolizumab plus chemotherapy versus Placebo plus chemotherapy for the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer.

SWOG S1706- A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer.

SWOG S2007– A Phase II Trial for patients with HER2-Negative Breast Cancer and Brain Metastases.

Cholangiocarcinoma

TransThera– A Phase 2, Open Label, Multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced Cholangiocarcinoma.

Chronic Lymphocytic Leukemia

Genentech — A prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of a combined regimen of Obinutuzumab and Venetoclax versus Fludarabine, Cyclophosphamide and Rituximab (FCR)/Bendamustine and Rituximab (BR) in for patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without Del (17P) or TP53 mutation.

Colorectal

Natera — BESPOKE CRC study for patients who have been diagnosed with State II or III CRC and will be tested with Signatera.

Xilis- Microorgano Sphere (MOS) Drug screen to lead care (MODEL) Precision oncology pilot trial in colorectal cancer.

Dysfunctional CVADs

Chiesi Ready 1 CUSA-081-HEM-01 — A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs).

Follicular Lymphoma

Epizyme/Parexel — A Phase 1b/3 Double-Blind, Randomized, Placebo-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat in Combination with Lenalidomide Plus Rituximab vs Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma.

Gallbladder

ECOG EA2197- Phase II/III trial to compare neoadjuvant Gemcitabine/Cisplatin and adjuvant Gemcitabine/Cisplatin in Stage T2 vs T3 incidental Gallbladder Cancer

Head and Neck

PDS Biotech/iQVIA — A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Patients with Recurrent and/or Metastatic Head and Neck Cancer and High-risk Human Papillomavirus-16 (HPV16) Infection.

NRG HN005- a randomized, Phase II/III trial of de-intensified radiation therapy for patients with early stage, P16 positive, non-smoking associated oropharyngeal cancer.

Hodgkin Lymphoma

BeiGene — A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with relapsed or refractory classical Hodgkin Lymphoma.

Merck C11- Phase 2 study of pembrolizumab and chemotherapy in patients with newly diagnosed classical Hodgkin Lymphoma.

Lymphoma/Myeloma

Trillium TTI-622-01 — A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

Seattle Genetics SGN35-032 — Dual cohort, open label, Phase 2 study of BV and CHP (A+CHP) in the frontline treatment of patients with PTCL with less than 10% CD30 expression.

ONO Pharma– An open-label phase II trial to investigate the efficacy and safety for patients with relapsed or refractory Primary Central Nervous System Lymphoma

Melanoma

Amgen Herpetic Infection 20130193 — A post-marketing prospective cohort study of Melanoma patients treated with Imlygic (Talimogene Laherparepvec) in clinical practice to characterize the risk of Herpetic infection among patients, close contacts, and health care providers, and long-term safety in treated patients.

BMS- A Phase 3, Open label, randomized, non-inferiority pharmacokinetic study of Nivolumab administered subcutaneously by autoinjector versus IV in patients with Stage IIIA/B/C/D or Stage IV adjuvant melanoma following complete resection.

Pfizer C4221016 — A phase 3, randomized, double-blind study of Encorafenib and Binimetinib plus Pembrolizumab versus placebo plus Pembrolizumab in previously untreated BRAF V600E/K mutation-positive participants with unresectable or metastatic melanoma.

Regeneron- A Phase 3 trial of Fianlimab (REGN-3767, Anti-LAG 3) + Cemiplimab vs. Pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.

Natera Bespoke- Immunotherapy monitoring clinical trial

Merkel Cell

ECOG EA6174- a Phase III study of adjuvant Pembrolizumab vs Observation in surgically treated Merkel Cell.

Non-Small Cell Lung Cancer

Altor Bioscience Quilt 2.023 — A study of ALT-803, a fusion protection activator of natural killer and T-cells, in combination with Pembrolizumab vs Pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer.

Merck MK3475-867 — A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA NSCLC (KEYNOTE-867).

Mersana/GOG3048 — Phase 1b, first in human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b.

Merck MK3475-A86- Phase III study of Pembrolizumab SC plus chemotherapy versus Pembrolizumab IV plus chemotherapy in 1L metastatic squamous or non- squamous NSCLC.

Iovance- A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer.

Alliance A151216- adjuvant lung cancer enrichment marker identification and sequencing trial

Alliance A081801– integration of immunotherapy into adjuvant therapy for resected non small cell lung cancer

ECOG EA5163/S1709- a randomized, Phase III study of first line immunotherapy alone or in combination with chemotherapy in induction/maintenance or post progression in advanced non-squamous non-small cell lung cancer with immunobiomarker signature-driven analysis

ECOG E4512– a component of the Alchemist trial-a randomized Phase III trial for surgically resected early stage non- small cell lung cancer: Crizotinib versus observation for patients with tumors harboring the anaplastic lymphoma kinase (ALK) Fusion protein

Ovarian Cancer

Aravive GOG-3059- Phase III, randomized, double-blind, placebo/Paclitaxel-controlled study of AVB-S6-500 in combination with Paclitaxel in patients with platinum resistant recurrent ovarian cancer.

Pancreatic Cancer

ECOG EA2185- a study comparing the clinical impact of pancreatic cyst surveillance programs

Alliance A021806- a Phase 3 trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer.

XBiotech- A phase I/II , double-blind, placebo-controlled trial examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer.

Prostate Cancer

Lilly CYCLONE 3- a  Phase 3, global, multicenter study to evaluate Abemaciclib in combination with abiraterone and prednisone for the treatment of patients with high-risk metastatic hormone-sensitive prostate cancer.

Renal Cancer

MK-6482-012 — An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as first line treatment in Participants with Advanced ccRCC.

Alliance A031704– This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body.

Small Cell Lung Cancer

Merck MK7339-013 — A phase 3 study of Pembrolizumab in combination with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparib, compared to concurrent chemoradiation therapy followed by placebo in participants with newly diagnosed treatment naïve limited-stage small cell lung cancer.

Cutaneous Squamous Cell Carcinoma

Regeneron Case — A prospective survivorship cohort study of adult patients with cutaneous squamous cell carcinoma undergoing treatment with Cemiplimab.

Castle Biosciences CBI-2019-cSCC-PVS-001 — Prospective Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma.

Alliance A091802– a Phase II, randomized trial of Avelumab plus Cetuximab vs. Avelumab alone in advance cutaneous squamous cell.

Urothelial Carcinoma

Alliance A032001— a Phase III randomized trial of maintenance Cabozantinib and Avelumab vs maintenance Avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer.

Immunomedics/PRA — A randomized open-label phase III study of Sacituzumab Govitecan versus treatment of physician’s choice in subjects with metastatic or locally advanced unresectable urothelial cancer.

Seattle Genetics RC48G001- A Phase 2 Mulit-cohort, open-label, multi-center clinical study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) in subjects with HER-2 expressing locally advanced unresenctable or metastatic urothelial carcinoma.

Acute Ischemic Stroke

Genentech- Tenecteplase in patients with Acute Ischemic Stroke. A pharmacokinetic study.

Parkinson’s

UCB BioPharma– A Phase 2A study to evaluate the efficacy, safety, and tolerability of oral UCB0599 in study participants with early Parkinson’s Disease.

Refractory Status Epilepticus 

Marinus- Phase IIb international, multi-center, placebo controlled study of Ganaxolone as an adjunctive treatment in adults suffering from partial onset seizures.

Contraception

Merck — A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant During Extended Use Beyond 3 Years in Premenopausal Females up to 35 Years of Age.

Bacterial Pneumonia

Sinnovent Pharmaceuticals– A Phase 3 study to evaluate the efficacy and safety of intravenous Imipenem/Cilastatin in comparison with Imipenem/Cilastatin/Relebactam in adults with hospital acquired bacterial pneumonia or ventilator associated bacterial pneumonia.

Cystic Fibrosis

Vertex VX20-121-102- A phase 3 randomized, double-blind, controlled study evaluating the efficacy and safety of VX-121 combination therapy in subjects with cystic fibrosis who are heterozygous for F508del and a minimal function mutation (F/MF).

Vertex VX20-121-103- A phase 3 randomized, double-blind, controlled study evaluating the efficacy and safety of VX-121 combination therapy in subjects with cystic fibrosis who are homozygous for F508del (F/F), or heterozygous for F508del and a gating (F/G)or residual function  (F/RF) mutation.

End Stage Renal Disease

Humacyte CLN-PRO-V007 — A Phase 3 study to compare the efficacy and safety of Humacyte’s Human Acellular Vessel with that of an Autologous arteriovenous fistula in subjects with End-Stage Renal disease.

Heart Failure

BioFourmis- This trial will be testing the efficacy of the BiovitalsHFTM platform, which is a smartphone compatible, evidence-based heart failure management tool.

Kidney Transplantation

VUMC Apollo — Long term Kidney Transplantation Outcomes Network

Incyte- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Pharmacokinetics of Parsaclisib in Participants with Primary AIHA.

Amyloidosis

Prothena- A Phase 3, Multicenter, Open-Label, Single-Arm, Efficacy and Safety Study of Birtamimab Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis.

Humacyte V005 — Use of HAV graft in trauma patients, including blunt trauma, penetrating trauma as well as iatrogenic trauma.

Phase Bio- REVERSE-IT- A Phase 3, Multicenter Study in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding, Requiring Urgent Surgery or Invasive Procedure

Contact Us

More Info on Clinical Trials

Find a Trial

Visit the Clinical Trials directory to find out all active clinical trials at the medical center.

Clinical Trials Overview

Clinical research plays a vital role in developing new drugs, new surgical procedures and devices, and new actions to advance our health.

Can I Join a Clinical Trial?

There are many reasons to participate in medical research and clinical trials. But before you do, it is important to consider whether the trial is right for you.

Clinical Trials: FAQs

Get all your questions answered about clinical trials at The University of Tennessee Medical Center.

How Does a Clinical Trial Work?

As part of the community of medical research, The University of Tennessee Medical Center’s scientists must follow specific guidelines to ensure participants’ safety and privacy.  

Clinical Trials With UTGSM

The University of Tennessee Medical Center pushes the frontiers of medicine through various research projects and clinical trials. Part of the way we do this is through clinical trials With the UT Graduate School of Medicine.